This Invention is a vaccine therapy using a combination of a nanoparticle delivery and human peptides to immunize against the development of heart failure or cardiac disease.
Stage of Development
In vivo data: A non-ischemic heart failure mouse model was used in which mice are vaccinated before the initiation of the heart failure protocol. These mice were then imaged by MRI to determine any effects on contractile properties of the heart with the vaccine in comparison to unvaccinated heart failure mice and control mice. The ejection fraction of the heart decreased in heart failure mice but remained higher in those animals treated with the therapy. Additional indicators such as End Diastolic Diameter and LV Mass were consistent with enhanced heart function as well as less fibrosis and normal heart size in the vaccinated mice group. This shows that there was significant preservation of function in those animals which were given the vaccine.
Competitive Landscape
Current therapies for heart failure have been limited, readmissions are common, and the mortality/morbidity remains high. While some heart failure cases can be corrected by treating the underlying cause, most treatments involve a balance of the right medications and lifelong management. The only definitive cure is heart transplantation though the donor availability remains low. Currently, there are no drugs or vaccines on the market to prevent the development of heart failure. The nanovaccine potentially provides a new non-invasive treatment to prevent, reduce, and inhibit heart failure or cardiac disease.
Competitive Advantages
• Novel therapeutic or prophylactic approach for a large unmet need
• Enhanced cardiac function in a non-ischemic heart failure animal model
• Increased ejection fraction, maintained normal heart size and reduced fibrosis in vaccine treated mice
• Enhances the patient’s immune system to prevent or minimize the heart failure
Intellectual Property
Provisional Patent filed November 18, 2019.
